Abstract
The purpose of this study was to evaluate the effect of
#Pentoxifylline on the reduction of #proteinuria of type 2 #diabetesmellitus patients
who were being treated with ACE and ARB. The study was prospective and
was achieved for six months at the Nephrology Clinic, UCCK,
between January and June 2016. The study included 162 patients with type
2 diabetes, diabetic patients with proteinuria above 500 mg / 24h
despite being treated with ACE Inhibitors and ARB. The patient group is
treated with Pentoxiphylline (oral) 400 mg 3 times a day. Proteinuria
for 24 hours was evaluated at the beginning of the study, then in the
first quarter and after six months treatment with Pentoxiphylline. In
the
other group 80 healthy individuals treated with Placebo. Both groups
have adapted the study to eliminating patients with comorbidities. To
the
all patients and subjects of the control group were taken #anamnesis,
also it was made objective examination, biochemical laboratory tests and
hematologic tests of Proteinuria for 24 hours. The standard deviation
and T-test are used for data analysis. During the six-month study of
these
patients treated with Pentoxiphyllin 400 mg (oral) #proteinuria was very
early. In the first three months, there was a decrease in proteinuria or
decreased protein loss through urine. The average age was 59.13, of
which 86 males and 76 females were involved in the research.
For more Biomedical open access journals please click on https://biomedres.us/
Fore more Research Article on BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.